Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given lateAdriano Pellicelli, M. Angélico, Christine M. Durand et al.|Digestive and Liver Disease|2014Cited by 103